Axitinib and nivolumab tested for mucosal melanoma
Tests axitinib with nivolumab in adults with untreated, advanced mucosal melanoma.
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Harrison and New York, United StatesSee the 2 sites
- Trial code
- Registry title
- Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 17 May 2022
- Expected to end
- May 2027
- Type of study
- Interventional
- Treatments tested
- Nivolumab and/or Ipilimumab
- Stereotactic Body Radiation Therapy (SBRT)
- axitinib
- Record updated
- 18 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or unresectable mucosal melanoma who have not had drug treatment for it before. They test axitinib with nivolumab.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Mucosal melanoma that cannot be removed by surgery or is advanced, starting in the head/neck, gut or urinary and genital area. At least 1 measurable tumour outside the brain, not in bone, is needed at first entry. ECOG performance status 0-2.
- Earlier treatment
- No earlier drug treatment for the melanoma, whether after surgery or for spread disease. For the added-treatment arms, the only earlier drug treatment allowed is nivolumab + axitinib on this trial.
Main reasons for not taking part
- Active autoimmune disease, or steroids or other immune-suppressing drugs within 14 days
- History of autoimmune nerve disease, heart muscle inflammation (myocarditis) or lung inflammation (non-infectious pneumonitis)
- Another active cancer needing ongoing drug treatment
- Serious heart disease, or high blood pressure that treatment does not control
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Histologic diagnosis of unresectable or advanced mucosal melanoma arising from the head/neck (e.g. sinonasal, oral cavity, conjunctival), gastrointestinal (e.g. anorectal, esophageal), or genitourinary (e.g. vulvovaginal, urethral) sites
- Measurable disease; Initial study entry: Subjects must have at least 1 extracranial, unresectable, non-bony lesion that is measurable radiographically (based on RECIST 1.1); Triplet arms: assessable disease required. RECIST 1.1 measurable disease is not required
- Prior therapy; Initial study entry: No prior systemic therapy (adjuvant or metastatic); Triplet arms: Only prior systemic therapy is nivolumab + axitinib on this trial
- ECOG performance status of 0-2
- Asymptomatic untreated brain metastases are allowed. Symptomatic brain metastases that have undergone local therapy with RT or surgery and have not required an increase in steroid dose in prior 2 weeks are allowed
- Screening laboratory parameters:; White blood cell (WBC) count ≥ 2000/μL; Absolute neutrophil count (ANC) ≥ 1500/μL; Platelets ≥ 100,000/μL; Hemoglobin (Hgb) ≥ 9 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN (< 3 mg/dL for subjects with Gilbert's disease); Estimated glomerular filtration rate (GFR) ≥ 30 mL/min;either Cockcroft Gault or a cancer-specific GFR Model such as the camGFR version 2 can be used
- Age ≥ 18 years
- Females of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception from screening, and must agree to continue using such precautions for 23 weeks after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. [Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).] Nonsterilized males who are sexually active with a female partner of childbearing potential must use 2 acceptable methods of effective contraception from Day 1 and for 31 weeks after receipt of the final dose of investigational product; Acceptable methods of effective contraception are described in the following:
- Barrier Methods (Male condom plus spermicide, cap plus spermicide, or diaphragm plus spermicide)
- Intrauterine Device Methods (Copper T, or Levonorgestrelreleasing intrauterine system (e.g., Mirena®), also considered a hormonal method)
- Hormonal Methods (Implants, hormone shot or injection, combined pill, mini pill, or Patch)
Who cannot take part
- Active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
- Other active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator
- Cardiovascular disease, including:; History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft (CABG) coronary angioplasty, or stenting within 6 months prior to study entry; Current Class II or higher congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system; Treatment-refractory hypertension defined as a blood pressure of systolic >150 mmHg and/or diastolic >90 mmHg despite adequate attempts at antihypertensive therapy
- Underlying hematologic issues including:; Congenital bleeding diathesis; GI bleeding requiring intervention within the past 6 months; Active hemoptysis within 42 days prior to study enrollment; Pulmonary emboli or deep vein thromboses (DVT) that are not stable on anticoagulation regimen
- History of motor neuropathy considered to be of autoimmune origin (e.g., Guillain- Barre Syndrome, Myasthenia Gravis)
- History of myocarditis
- History of, or any active evidence of non-infectious pneumonitis
- History of severe allergic reactions to an unknown allergen or any components of the study drugs
- Other serious infectious illnesses (e.g., active symptoms of COVID-19 infection or a post-infectious symptomatic autoimmune syndrome, serious bacterial infections requiring antibiotics)
- Genetic or autoimmune condition causing heightened radio sensitivity
- Women who are breastfeeding or who are pregnant as evidenced by a positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performed within 14 days of the first dose of study drug and by a urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of the first dose of study drug(s)
Where in United States
- Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Alexander Shoushtari, MDTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Alexander Shoushtari, MDTaking people
About the trial
What the trial wants to find out
The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.
Read full original descriptionShow less
The researchers think that a combination of axitinib and nivolumab may help people with this disease because both drugs target and block proteins that play a role in cancer cell survival and growth. The researchers think the drugs may be more effective if given in combination rather than on their own.
The group in the trial
- Axitinib and Nivolumab for the Treatment of Mucosal MelanomaTreatment being tested
This is a single center trial enrolling up to 20 total evaluable patients with unresectable primary or advanced mucosal melanomas arising from the head and neck, gastrointestinal, or genitourinary tract to receive frontline therapy with nivolumab IV 480mg q4 weeks plus axitinib 5mg PO twice daily. A Simon 2-stage design will be utilized. Upon progression with good tolerance, addition of stereotactive body radiation therapy (SBRT) or CTLA-4 blockade to continued nivolumab plus axitinib will be offered to patients depending on the type of progression. For patients with local or oligometastatic progression, stereotactic body radiotherapy (SBRT) will be added; for patients with progression in a site of prior radiotherapy or with multifocal or distant progression not amenable to SBRT, ipilimumab 1mg/kg IV q3 weeks for up to 4 doses will be added.
Treatment: Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), and axitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2 Study of Axitinib + PD-1 Blockade in Mucosal Melanoma With Pilot Addition of Stereotactic Body Radiotherapy or Ipilimumab in Select Progressors
- Plain-language title
- Axitinib and nivolumab tested for mucosal melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 February 2026